Key result
Higher baseline serum ANGPTL8/betatrophin levels were associated with a significantly decreased risk of developing metabolic syndrome over 3.5 years in both males (OR 0.92) and females (OR 0.84).
Why the study?
Do baseline serum ANGPTL8/betatrophin levels predict the development of metabolic syndrome in adults?
Population
153 adults without metabolic syndrome from a community-based cohort
Design
Cohort
Follow-up
3.5 years
Authors
Loading...
Suggests ANGPTL8 as potential protective biomarker; hypothesis-generating and requires confirmation before clinical application.
Cohort (n=153)
No
Do baseline serum ANGPTL8/betatrophin levels predict the development of metabolic syndrome in adults?
Odds Ratio: 0.84 (95% CI 0.74–0.96)
p-value: p=0.010
Serum ANGPTL8/betatrophin levels may serve as a useful biomarker for predicting the onset of metabolic syndrome in adults.
Wang et al. (2016) conducted a cohort in Metabolic Syndrome (n=153). Higher serum ANGPTL8/betatrophin levels vs. Lowest quartile of ANGPTL8/betatrophin levels was evaluated on Incidence of metabolic syndrome (females) (OR 0.84, 95% CI 0.74-0.96, p=0.010). Higher baseline serum ANGPTL8/betatrophin levels were associated with a significantly decreased risk of developing metabolic syndrome over 3.5 years in both males (OR 0.92) and females (OR 0.84).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: